Tony Arulanandam
Chief Executive Officer & Founder Synaptimmune Therapeutics
Seminars
Thursday 30th July 2026
Accelerating T‑Cell Engager & Co‑Stimulatory Therapeutics Through Patient‑Centric Tumor Model Integration
12:00 pm
- Showcasing a strategic model cascade across ex vivo, organoid and in vivo systems to map early TCE and co stimulatory biology; defining activation thresholds, uncovering liabilities, and identifying where TME driven suppression limits efficacy
- Spotlighting patient derived explants and tumor derived organoids to capture real human immune suppression, spatial constraints and tumor intrinsic resistance mechanisms; revealing insights that subcutaneous or cell only models routinely miss
- Demonstrating a rigorous validation pathway from ex vivo to PDX, verifying mechanism of action, multi day durability, exposure–response and combination potential in human relevant settings, enabling confident prioritization of next generation TCE and co stimulatory candidates for solid tumors
